Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
AssigneeBoard of Regents, The University of Texas System
InventorsJacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.
Claims82
A method of treating cancer in a subject comprising administering an effective amount of poziotinib to the subject, wherein the subject has been determined to have one or more epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistant mutations.
The method of any of claims 15-18, wherein the one or more EGFR exon 20 mutations comprise D770insNPG, S784F, R776C, S768I, V774M, S768I, H773insAH, H773insNPH, V774A, V769L, V769M, S768dupSVD, A763insLQEA, L792H, G796D, S784F, C775Y and/or S811F.
The method of claim 41, wherein the genomic sample is isolated from saliva, blood, urine, normal tissue, or tumor tissue.
A pharmaceutical composition comprising poziotinib for use in a subject determined to have one or more EGFR TKI resistant mutations.
A method of predicting a response to poziotinib alone or in combination with a second anti-cancer therapy in a subject having a cancer comprising detecting a EGFR TKI resistant mutation in a genomic sample obtained from said patient, wherein if the sample is positive for the presence of the EGFR TKI resistant mutation, then the patient is predicted to have a favorable response to the poziotinib alone or in combination with an anti-cancer therapy.
Dependencies are inferred from the claim text.